Business UpdateApr 28, 2026, 04:09 PM
MDGL Rezdiffra 2025 Sales $958.4M; Annualized Q4 Rev >$1B
AI Summary
Madrigal Pharmaceuticals reported strong performance for Rezdiffra in 2025, achieving $958.4 million in net sales and exiting the year with quarterly revenue annualizing over $1 billion. The company established Rezdiffra as the foundational therapy in MASH, with over 36,250 patients on therapy and patent protection extended to 2045. Madrigal also expanded its pipeline to over ten programs and will hold its Annual Meeting on June 17, 2026, to vote on director elections and new stock plans.
Key Highlights
- Rezdiffra 2025 net sales reached $958.4 million.
- Quarterly revenue for Rezdiffra annualized over $1 billion by year-end 2025.
- Over 36,250 patients were on Rezdiffra therapy by year-end 2025.
- U.S. F2/F3 MASH population grew nearly 50% to 460,000 patients in two years.
- Rezdiffra patent protection was granted into 2045.
- Pipeline expanded to over ten programs, including oral GLP-1 and DGAT-2 inhibitor.
- Annual Meeting on June 17, 2026, to elect directors and approve stock plans.
- Board recommends approval of 2026 Stock Plan and 2026 Employee Stock Purchase Plan.